BI 456906

BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist

N/A Amino Acids · MW: N/A

Ask AI About This

Amino Acids

N/A

Molecular Weight

N/A

Half-life

Approximately 1 week

Research Score

4.1

Studies

Storage

Store lyophilized at -20°C, reconstituted at 2-8°C

What is BI 456906?

BI 456906 is a Boehringer Ingelheim investigational GLP-1/glucagon dual agonist explored for obesity and metabolic liver disease. The compound is intended to promote fat loss while improving glucose handling.

Key Benefits & Mechanisms

weight reduction

improved glucose control

lower liver-fat burden

enhanced satiety

Research Summary

Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.

Related Peptides

Oxyntomodulin

Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide

Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.

Weight Management

Cotadutide

MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist

Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.

Weight Management

Mazdutide

IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist

Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.

Weight Management

Dulaglutide

Recombinant GLP-1 receptor agonist Fc fusion protein

Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.

Weight Management